Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association of CD31 and p53 With Survival of Ovarian Cancer Patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The Influence of Cyst Emptying, Lymph Node Resection and Chemotherapy on Survival in Stage IA and IC1 Epithelial Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Bevacizumab combined with chemotherapy has recently shown promising efficacy in recurrent high-grade glioma. Phosphatase and tensin homolog (PTEN) mutation in glioblastoma multiforme (GBM) patients causes abnormally high activity of the pathways of Phosphatidylinositide 3-kinases (PI3K), Protein Kinase B (AKT), and the mammalian target of rapamycin (mTOR) and is associated with unfavorable prognosis. Temsirolimus, an mTOR inhibitor, has been well-tolerated in monotherapy, but with limited effects. The combination of temsirolimus and antibodies to vascular endothelial factor (VEGF) has not yet been investigated, but with the hypothesis that temsirolimus might provide complimentary therapeutic benefit in combination with bevacizumab, we included patients with progressive GBM after bevacizumab in an open phase II study.
OriginalsprogEngelsk
TidsskriftAnticancer Research
Vol/bind33
Udgave nummer4
Sider (fra-til)1657-60
Antal sider4
ISSN0250-7005
StatusUdgivet - apr. 2013

ID: 42236240